13th World Congress on Advances and Innovations in Dementia (CSE)

Chiba Prefecture - 13th World Congress on Advances and Innovations in Dementia (CSE)

水曜日 22.5.2019
から 8:00
木曜日 23.5.2019
へ 17:00
Chiba Prefecture
JPChiba PrefectureVenue will be informed to the Registered Participants
0 客室乗務員
13th World Congress on Advances and Innovations in Dementia
About ConferenceAfter the successful completion of 12th World Congress on Advances and Innovations in Dementia we take the opportunity to announce. Dementia congress 2019, 13th World Congress on Advances and Innovations in Dementia, which is held during May 22-23, 2019 at Tokyo Japan. The main theme of our conference is "Exploring the Challenges and Excellence in Dementia Research" which covers wide range of critically important sessions. It’s a platform to bring all the neuroscientists together to share their experiences it’s the amalgam of scientific research as well as innovative disorders are diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer's disease, brain tumours, epilepsy, Parkinson's disease, and stroke, dementia as well as less familiar ones such as front temporal dementia.In the present day scenario a wide population of mankind are plagued by mental and neurological illnesses, with almost 165 million people or 38 percent of the population suffering each year from a brain disorder. With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden, it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year. An estimated 6.8 million people die every year as a result of neurological disorders public health challenges describes and discusses the increasing global public health importance of common neurological disorders such as dementia, epilepsy, headache disorders, multiple sclerosis, neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, stroke and traumatic brain Alliance provided fund of $650 million to fuel the research on mental illness. NARSAD Young Investigator Grant provides $30,000 per year on research in Neural and behavior disorders such as dementia, schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. Brain tumor research receives less than 1% (0.7%) of national cancer research spending in the UK. In order to accelerate the research in the field of Neuroscience Conference Series organizes different conference series Organization    3000+ Global Events    25 Million+ Visitors    25000+ unique visitors per conference    70000+ page views for every individual conference    Unique Opportunity! Online visibility to the Speakers and ExpertsHighlights:Dementia    Vascular DementiaAlzheimers disease    Neurodegenerative DiseasesBrain diseases    Animal Models in DementiaAmyloid protein in dementia    Diagnosis of DementiaNursing care in Dementia    Dementia ManagementDrug Development in Dementia    Recent Advancement in Treatments of DementiaClinical Trials & Case Reports in Dementia    Aging and Progressive dementia Who should attend?    Neuroscientist    Neuroanatomist    Neurobiologist    Neurochemist    Neurological Surgeon    Neurologist    Neuropathology’s    Neuropharmacologist    Neurophysiologist    Neuropsychologist    Neuroradiology’s    psych biologist    Biological Psychologist    Psychiatrist    Neuroscience Nurse     Psychophysicist     Professors     Students     Neuro drug ManufacturersBenefits of attending:    Networking Opportunities    Grow Your Professional Network    Build Your Knowledge Base    Expand Your Resources    Meet Experts & Influencers Face to Face    Learning In a New Space    Break Out of Your Comfort Zone    New Tips & Tactics    Greater Focus    The Serendipity of the Random WorkshopWho should sponsor/exhibit:    Pharmaceuticals    Drug Manufacturers    Hospitals    Educational Institutes    Research Centres    Hospitals    Associations    Societies
SessionsTrack 1: DementiaDementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Other common symptoms include emotional problems, problems with language, and a decrease in motivation. A person's consciousness is usually not affected. A dementia results in a change from a person's usual mental functioning and a greater decline than one would expect due to aging. These diseases also have a significant effect on a person's 2:  Alzheimers diseaseAlzheimers disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia. The most common early symptom is difficulty in remembering recent events short-term memory loss. [As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioural issues. As a person's condition declines, they often withdraw from family and society.  Gradually, bodily functions are lost, ultimately leading to 3: Vascular DementiaVascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. This death of brain cells can cause problems with memory, thinking or reasoning. Together these three elements are known as cognition. When these cognitive problems are bad enough to have a significant impact on daily life, this is known as vascular 4: Frontotemporal dementiaFrontotemporal dementia is an uncommon type of dementia that mainly affects the front and sides of the brain (frontal and temporal lobes) and causes problems with behaviour and language. Dementia mostly affects people over 65, but front temporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, Frontotemporal dementia tends to develop slowly and get gradually worse over several years. Frontotemporal dementia is misdiagnosed as a psychiatric problem or as Alzheimer's disease. Track 5: Neurodegenerative DiseasesNeurodegenerative diseases cause your brain and nerves to deteriorate over time. They can change your personality and cause confusion. They can also destroy your brain’s tissue and nerves. Some brain diseases, such as Alzheimer’s disease, may develop as you age. They can slowly impair your memory and thought processes. Other diseases, such as Tay-Sachs disease, are genetic and begin at an early 6:  Brain diseasesThe brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic 7: Parkinson’s diseasesParkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its 8: Anxiety & DepressionApathy, depression and anxiety are common conditions experienced by people with dementia. They are known as psychological conditions because they can affect a person’s emotional and mental health. Anxiety is more than just feeling stressed or worried. Anxious feelings are a normal reaction to a situation where a person feels under pressure and usually pass once the stressful situation has passed, or the ‘stressor’ is removed. Depression affects how a person feels about themselves. A person may lose interest in work, hobbies and doing things he or she normally enjoys. Some people may lack energy, have difficulty sleeping or sleep more than usual, while some people feel anxious or irritable and find it hard to 9: Animal Models in DementiaAnimal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development have been carried out. Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development has been carried 10: Amyloid protein in dementiaAmyloid Plaques One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP)Track 11: Diagnosis of dementiaDiagnosing dementia and determining what type it is can be challenging. A diagnosis of dementia requires that at least two core mental functions be impaired enough to interfere with daily living. They are memory, language skills, ability to focus and pay attention, ability to reason, solve problem and visual perception Track 12: Nursing care in DementiaNurses provide the specialist dementia support that families need. When things get challenging or difficult, our nurses work alongside people with dementia, and their families: giving them one-to-one support, expert guidance and practical 13: Dementia ManagementThere is no cure for dementia, so the chief goals of treatment are to:a. Maintains quality of lifeb. Enhances cognition, mood and behaviourc. Fosters a safe environmentd. Promotes social engagementTrack 14: Drug Development in DementiaDementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug 15: Recent Advancement in Treatments of DementiaEpidemiological studies show that, worldwide, the number of people aged over 65 will increase substantially in the next decades and that a considerable proportion of this population will develop dementia. Ample evidence shows that ageing is associated with a high rate of painful conditions, irrespective of cognitive status. The number of patients with dementia who will experience painful conditions is therefore likely to 16: Clinical Trials & Case Reports in DementiaThe goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.
AGENDA 2018----------------------------------------2019 Upcoming Soon----------------------------------------Day 01 September 17, 201809:00-09:30 Registrations09:30-09:55 Opening Ceremony09:55-10:00 Introduction10:00-11:00 Title: Omental transposition to the brain for alzheimer’s diseaseHarry S Goldsmith, University of California, USAGroup PhotoNetworking & Refreshments Break: 11:00-11:20 @ FoyerWorkshop11:20-12:20 Title: Early intervention through localised gamesChristel Goh, Founder of Play Huahee, SingaporeSession: Dementia | Alzheimers Disease | Diagnosis of Dementia | Dementia Management | Animal Models inDementia| Drug Development in Dementia| Recent Advancement in Treatments of DementiaSession IntroductionSession Chair: Harry S Goldsmith, University of California, USA12:20-12:50Title: How to improve caregiving self-efficacy on managing disruptive behavior of dementia client?ARCT study on an evidence-based psychosocial interventionTang Wai Kit, Castle Peak Hospital, Hong KongLunch Break: 12:50-13:40 @ Food Exchange, Level 213:40-14:10 Title: Innovative technologies for dementia care in the homeAlessandra Doolan, The Health and Technology Advisory Group, Sydney14:10-14:40 Title: Autologous neural cell therapy reverses a dementia syndrome in older pet dogsThomas Duncan, University of Sydney, Australia14:40-15:10Title: Psychosocial wellbeing among family carer’s of persons with late On-set dementia - homebased palliative careSam Sangeeth, Bishop Heber College, India15:10-15:40Title: E-BABE-The hidden relation, clues of autism, adhd, and depression which reveal the effective causeand cure16Van Duy Dao, Pharmacist, VietnamNetworking & Refreshments Break: 15:40-16:00 @ FoyerPanel Discussions & B2B MeetingsDay 2 September 18, 2018Polaris IKeynote Forum10:00-11:00 Title: Single voxel spectroscopy on two memory-enhancing drugs proposes glutamate modulationMichael Entzeroth, Chief Scientific Officer of Cennerv Pharma, SingaporeNetworking & Refreshments Break: 11:00-11:20 @ FoyerWorkshop11:20-12:20Title: Adopting laughter therapy to get dosage of happy hormones while having dementia. Helping toremove stress /depression and anxiety caused by a family member having , Specialist Diploma in Early Childhood Education, SingaporePoster Presentations @ 12:20-13:00DC001 Title: Effect of ETAS in predementia cognitive disorder in young ageNatalia Mikhaylichenco, Nevron International Medical Center, RussiaDC002Title: Missed the proper diagnosis timing: Dementia diagnosis process of the elderly with dementiafrom the perspective of middle-aged ***** children in KoreaJeong Sun Kim, Chonnam National University, Republic of KoreaDC003Title: Potential application of human neural crest-derived nasal stem cells in models of Alzheimer’sdisease as a clinically applicable therapyJung Yeon Lim, The Catholic University of Korea, Republic of KoreaDC004Title: Brain insulin resistance: Targeting PI3K/AKT/GSK3-β pathway in IntracerebroventricularStreptozocininduced rat model of Alzheimer’s diseaseAnsab Akhtar, Panjab University, IndiaDC005Title: Assessment of pure compound delineating ageing: Targeting receptor of advanced Glycationend productsSana Khan, PakistanLunch Break: 13:00-14:00 @ Food Exchange, Level 2Session: Dementia | Alzheimers Disease | Neurodegenerative Diseases | Diagnosis of DementiaSession IntroductionSession Chair: Harry S Goldsmith, University of California, USA14:00-14.45 Title: Dementia and the cycle of role reversal: Always a matriarchNaomi Lilly, Duke University, USA14:45-15:30 Title: Cardiovascular risk and mild cognitive impairment for alzheimer diseaseLina Maria Lopez Roa, Universidad del Cauca, USA15:30-16:45Title: Meaningful measures of metabolic and appetite perturbations in dementia prevention,diagnosis, and careArtemissia-Phoebe Nifli, Technological Research Center of Thessaly, GreeceAwards and Closing CeremonyNetworking & Refreshments Break: 16:45-17:00 @ FoyerPanel DiscussionB2B Meetings
Please contact the event manager Marilyn ( ) below for:- Multiple participant discounts- Price quotations or visa invitation letters- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)- Event sponsorshipNO REFUNDS ALLOWED ON REGISTRATIONSPrices may go up any time. Service fees included in pricing.-----------------------------------------------------------------This event is brought to you by:Conference Series - NewYorkEventsListhttp://
Pop Title
Pop TextPop Button1Pop Button2